# Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer

> **NCT07667335** · PHASE1,PHASE2 · RECRUITING · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 27 (estimated)

## Conditions studied

- Locally Advanced Bladder Urothelial Carcinoma
- Locally Advanced Renal Pelvis Urothelial Carcinoma
- Locally Advanced Ureter Urothelial Carcinoma
- Metastatic Bladder Giant Cell Urothelial Carcinoma
- Metastatic Renal Pelvis Urothelial Carcinoma
- Metastatic Ureter Urothelial Carcinoma
- Stage IIIB Bladder Cancer AJCC v8
- Stage IV Bladder Cancer AJCC v8
- Stage IV Renal Pelvis Cancer AJCC v8
- Stage IV Ureter Cancer AJCC v8
- Unresectable Bladder Urothelial Carcinoma
- Unresectable Renal Pelvis Urothelial Carcinoma
- Unresectable Ureter Urothelial Carcinoma

## Interventions

- **DRUG:** Quemliclustat
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **DRUG:** Enfortumab Vedotin
- **PROCEDURE:** Magnetic Resonance Imaging
- **BIOLOGICAL:** Pembrolizumab
- **PROCEDURE:** Biopsy Procedure

## Key facts

- **NCT ID:** NCT07667335
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-10-15
- **Primary completion:** 2029-07-16
- **Final completion:** 2029-07-16
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2026-09-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07667335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07667335, "Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07667335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*